

S 1276

Cannabidiol Research Expansion Act

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: May 25, 2017

Current Status: Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure:

Latest Action: Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221) (May 25, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/1276>

Sponsor

Name: Sen. Feinstein, Dianne [D-CA]

Party: Democratic • **State:** CA • **Chamber:** Senate

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Durbin, Richard J. [D-IL]	D · IL		May 25, 2017
Sen. Ernst, Joni [R-IA]	R · IA		May 25, 2017
Sen. Grassley, Chuck [R-IA]	R · IA		May 25, 2017
Sen. Tillis, Thomas [R-NC]	R · NC		May 25, 2017
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Jul 11, 2017
Sen. Kaine, Tim [D-VA]	D · VA		Nov 8, 2017
Sen. Klobuchar, Amy [D-MN]	D · MN		Mar 19, 2018

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	May 25, 2017

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

No related bills are listed.

Cannabidiol Research Expansion Act

This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted.

The bill expands the authority for: (1) conducting medical research on cannabidiol and other nonpsychoactive components of marijuana, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes.

The Department of Justice shall register an applicant to manufacture or distribute cannabidiol or marijuana for the purpose of commercial production if approved by HHS.

Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients.

The bill terminates four years after enactment.

Actions Timeline

- **May 25, 2017:** Introduced in Senate
- **May 25, 2017:** Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)